Systemic Inflammation Modifies the Efficacy of Bevacizumab Added to Atezolizumab Plus Chemotherapy for Advanced Non-Squamous Non-Small Cell Lung Cancer: A Multicenter Retrospective Study.

Although the interaction between CRP level and bevacizumab treatment did not reach statistical significance when CRP cutoffs of 2 mg/dL ( p for interaction = 0.24) were used, bevacizumab continued to show a tendency toward greater efficacy in the CRP‐high group, consistent with the primary analysis. 4 Discussion This multicenter retrospective study demonstrated that the survival benefit of bevacizumab combined with atezolizumab and chemotherapy differed according to baseline systemic inflammation, as assessed by CRP level.

also in 111,027 other papers